TY - JOUR
AU - Feldmann, G.
AB - Abstract BACKGROUND: The aim of our study was to measure concentrations of vascular endothelial growth factor (VEGF), platelet endothelial cell adhesion molecule-1 (PECAM-1) CD31 and vascular cell adhesion molecules (VCAM-1) in the follicular fluid of women treated with assisted reproduction technology to determine whether these proteins might be outcome markers. METHODS: Follicular fluid was collected from 75 patients ≤40 years undergoing oocyte retrieval procedures at our tertiary hospital during 1997 and 1998: 50 with tubal disease, 12 with endometriosis, and 13 whose partners had been diagnosed with severe oligoasthenoteratozoospermia. This retrospective analysis considered age and information about treatment and outcome for all these women who had undergone fewer than three assisted reproduction attempts. RESULTS: Nineteen women became pregnant (defined by human chorionic gonadotrophin concentrations and embryonic cardiac activity 1 month after follicular aspiration); 56 did not. Women did not differ significantly in their follicular fluid concentrations of VEGF, sCD31 and VCAM-1 according to cause of infertility, or assisted reproduction outcome, or age. Follicular fluid concentrations of VEGF were significantly correlated with the number of gonadotrophin ampoules administered (P < 0.012), and follicular fluid concentrations of sVCAM-1 with the fertilization rate (P < 0.01). Follicular fluid concentrations of VEGF and sVCAM-1 were also correlated (P < 0.007). CONCLUSIONS: Our results do not suggest that VEGF, CD31, or sVCAM-1 in follicular fluid predict assisted reproduction outcome, especially among patients ≤40 years old. The correlation of a high fertilization rate and sVCAM-1 in follicular fluid suggests that sVCAM-1 might be a marker of fertilization. endometriosis, follicular fluid, CD31, VCAM-1, VEGF Introduction Interest has recently focused on possible interactions between cytokines, growth factors and mitogens in the ovary (Adashi, 1992; Moncayo and Moncayo, 1995; Elchalal and Schenker, 1997). Vascular endothelial growth factor (VEGF) is a heparin-binding glycoprotein that enhances vascular permeability, is mitogenic for endothelial cells and promotes angiogenesis in normal and tumoral tissues (Ferrara et al., 1991, 1992). In the ovary, VEGF is produced both by granulosa and thecal cells (Ravindranath et al., 1992; Kamat et al., 1995). Recent study of macaque granulosa cells suggests that VEGF expression increases in response to gonadotrophins such as LH, FSH and human chorionic gonadotrophin (HCG) (Christenson and Stouffer, 1997). VEGF has been also implicated in the pathogenesis of capillary leakage, which in turn is a major mechanism of ovarian hyperstimulation syndrome (OHSS), a severe complication of IVF procedures (Yan et al., 1993; Neulen et al., 1995; Abramov et al., 1997; Elchalal and Schenker, 1997). In women with normal non-stimulated cycles and those undergoing IVF, the local VEGF production in follicular fluid (follicular fluid) is correlated with the degree of follicular luteinization (Lee et al., 1997; Anasti et al., 1998). Progesterone also appears to play a role in determining VEGF concentration in follicular fluid (Moncayo et al., 1998). A positive correlation has also been observed between follicular fluid VEGF concentrations and patient age, especially in patients ≥38 years undergoing IVF (Friedman et al., 1997; Manau et al., 2000). Recently, it has been reported that elevated VEGF concentrations in follicular fluid might predict poor conception rates after IVF (Friedman et al., 1998). Platelet endothelial cell adhesion molecule-1 (PECAM-1 or CD31) and vascular cell adhesion molecule-1 (VCAM-1) are transmembrane glycoproteins belonging to the immunoglobulin superfamily (Gearing et al., 1993; Almendro et al., 1996). These molecules are known to be essential mediators of white blood cell adhesion and extravasation during inflammatory and immune reactions (Marik and Lo, 1996; Cotran and Mayadas-Norton, 1998). VCAM-1 and CD31 have also been used to assess angiogenesis; the expression of each is characterized by the release of an active soluble form (Banks et al., 1993; Gearing et al., 1993; Goldberger et al., 1994). Recent investigation of the plasma and peritoneal fluid concentrations of soluble VCAM-1 (sVCAM-1) indicates that, like VEGF, VCAM-1 seems to play a role in the pathogenesis and progression of OHSS (Daniel et al., 1999). To our knowledge, VCAM-1 and CD31 have never been studied in follicular fluid. The aim of our study was to assess the concentrations of VEGF, sVCAM-1 and sCD31 in the follicular fluid of 75 women seeking to become pregnant with assisted reproductive technology and to assess their utility as markers or predictors of IVF outcome. Materials and methods Follicular fluid was collected from 75 consecutive patients ≤40 years who were undergoing oocyte retrieval for IVF procedures at the Department of Obstetrics and Gynaecology in the Bichat Claude Bernard tertiary hospital during 1997 and 1998. Population The 75 patients were divided into three groups according to the cause of their infertility: for 50 women it was due only to laparoscopically confirmed tubal disease, without any male factors; 12 women had laparoscopy-proven severe endometriosis with no male factors and 13 women had partners diagnosed with severe oligoasthenoteratozoospermia that required intracytoplasmic sperm injection (ICSI). The records of all IVF and ICSI procedures were retrospectively reviewed to collect the following data: age, duration of stimulation, total ampoules of administered gonadotrophins, plasma oestradiol concentration on the day of HCG administration, number of retrieved oocytes, fertilization rate and pregnancy rate. None of them had more than three attempts at assisted reproduction and no patient was included twice considering sequential cycles. Fifty-six women did not become pregnant after assisted reproduction (group 1). Pregnancy (n = 19, group 2) was defined by significant HCG concentrations and the observation of embryonic cardiac activity during the transvaginal ultrasound examination performed 1 month after follicular aspiration. IVF stimulation procedure All patients underwent a standard stimulation protocol, described below. First, hormonal down-regulation was begun with a gonadotrophin-releasing hormone (GnRH) agonist (Triptorelin, Decapeptyl; Ipsen/Biotech, Paris, France). This treatment started on the third day of the menstrual cycle preceding IVF and was given i.m. at a daily dose of 0.1 mg for a minimum of 2 weeks. When the serum oestradiol concentration was <50 pg/ml, three ampoules of human menopausal gonadtotrophin (Menotropin, Humegon 75 IU; Organon, Saint-Denis, France) for 26 women or two ampoules of recombinant FSH (Follitropin alpha, Gonal-F 75 IU; Serono, Boulogne, France; or Follitropin beta, Puregon 100 IU; Organon, Saint-Denis, France) for 49 women were given i.m. each evening in addition to 0.05 mg of GnRH agonist. Follicular development was monitored by ultrasound with a 5 MHz transvaginal probe. The dose of gonadotrophin stimulation was then adjusted according to plasma oestradiol concentrations and the size of the ovarian follicles evaluated by ultrasound examination. Finally, when the plasma oestradiol concentration was >1800 pg/ml and when at least two follicles with a diameter of 20 mm were observed by ultrasound examination, 10 000 IU of HCG was given i.m. to induce follicular rupture. Transvaginal follicular aspiration was performed 34–36 h after the HCG injection, under general anaesthesia using propofol (Diprivan; Zeneca, Cergy, France). After oocytes were identified and separated, the clear follicular fluid was collected and pooled for each woman. When blood contamination was observed, follicular fluid was discarded. This study considered follicular fluid from only one cycle for each patient. All samples were immediately centrifuged at 400 g for 10 min and the supernatant stored frozen at –40°C until they were assayed. Determination of VEGF, sVCAM-1 and sCD31 concentrations in follicular fluid These concentrations were assessed with the appropriate enzyme-linked immunosorbent assay test kits for human VEGF, human sVCAM-1, and human sCD31 (R&D Systems Minneapolis, USA). All samples were run in duplicate. For VEGF, VCAM-1 and CD31, all samples were diluted to 1/4, 1/20 and 1/5 respectively with the appropriate dilutant provided by the manufacturer. For VEGF, the sensitivity of the test was 9 pg/ml. The intra-assay and inter-assay coefficients of variation (CV) were 3.5 and 7% respectively. For sVCAM-1, the sensitivity of the assay was 2 ng/ml, and the intra-assay and inter-assay CV were 5 and 9% respectively. Finally, for sCD31, the sensitivity of the assay was 0.05 ng/ml, and the intra-assay and inter-assay CV were 7 and 6% respectively. Statistical analysis Student's t-test, the Kruskal-Wallis test and a Spearman correlation were all used for the statistical analysis. P < 0.05 was considered as significant. The sample size of our study provided a power of 97% for the t-test to detect the difference in VEGF concentrations previously observed (Friedman et al., 1998), with the variance estimates they reported. Results Table I summarizes the characteristics of the 75 patients. The three groups defined according to the origin of their infertility did not differ significantly for any of the characteristics assessed: mean age, total number of gonadotrophin ampoules administered, oestradiol concentration on day of HCG injection, number of retrieved oocytes, and fertilization rate. Similarly, they did not differ significantly with respect to follicular fluid concentrations of VEGF, sCD31 or sVCAM-1. No patient in this study developed OHSS. Moreover, the assisted reproduction outcome was not related to follicular fluid concentrations of VEGF, sCD31 or sVCAM-1. Group 1 (the 56 women who did not become pregnant) and group 2 (the 19 women who did become pregnant) did not differ significantly for any of these growth factor concentrations, as Table II shows. Of the 19 women who became pregnant, five miscarried during the first trimester. The remaining pregnancies resulted in viable offspring. As with the previous comparisons, these two groups of women (14 who gave birth at term and five who had miscarriages) did not differ significantly in their follicular fluid concentrations of VEGF, sCD31 or sVCAM-1 (Table III). In this study, 15 patients were ≥38 years old. As Table IV shows, we compared them with the group of women <38 years, and found no statistically significant differences in the follicular fluid concentrations of VEGF, sCD31, or sVCAM-1. The only significant difference between the two groups concerned the oestradiol peak on the day HCG was administered; it was higher among the younger women. Finally, the angiogenic factors (VEGF, CD31, and VCAM-1) we examined were not significantly correlated with patient age, the number of oocytes retrieved, or the concentration of oestradiol peak. As in recent studies (Friedman et al., 1998; Manau et al., 2000), follicular fluid concentrations of VEGF were weakly but significantly correlated with the number of gonadotrophin ampoules administered (P < 0.012) (Figure 1A). Follicular fluid concentrations of sVCAM-1 were also correlated with the fertilization rate (P < 0.01) (Figure 1B) and the follicular fluid concentration of VEGF (P < 0.007) (Figure 1C). Discussion Several authors have demonstrated that VEGF is produced by granulosa cells and released into the follicular fluid after gonadotrophin stimulation (Neulen et al., 1995; Christenson and Stouffer, 1997). Recently, it was observed that follicular fluid concentrations of VEGF were positively correlated with patient age, in particular, for patients ≥38 years undergoing IVF (Friedman et al., 1997). These authors subsequently observed a correlation between the follicular fluid concentration of VEGF and IVF outcome (conception rate) (Friedman et al., 1998), with high concentrations associated with poor outcome. They therefore suggested that follicular fluid VEGF might be a marker of a decreased ovarian reserve and of a hostile follicular environment. Recently, the same positive correlation between high concentration of follicular fluid VEGF and the patient's age was reported (Manau et al., 2000). Our study did not confirm their findings that VEGF concentrations are positively correlated with patient age and a low conception rate. Like them, we did observe a moderate increase in follicular fluid concentrations of VEGF in women ≥38 years old undergoing follicular aspiration, compared with younger women, but the difference was not statistically significant. Finally, in our study we obtained (-46.3; 1419.9) as 95% CI of the difference in the follicular fluid VEGF between groups 1 and 2 (Table II) which makes unlikely any such correlation with IVF outcome noted by Friedman et al. (1998). Furthermore, we found no statistically significant correlation between the follicular fluid concentrations of sCD31 or sVCAM-1 and patient age. Our results also indicated that follicular fluid concentrations of VEGF, sCD31 and sVCAM-1 were similar for the three different causes of infertility studied, i.e. tubal factors, endometriosis, or male factors. This result must be interpreted cautiously in view of the fairly small size of the latter two groups. Thus, contrary to the results obtained by Friedman et al. (1998), our data suggest that VEGF concentrations in follicular fluid do not predict assisted reproduction outcome. However, some authors (Van Blerkom et al., 1997) have shown that the VEGF measurements of follicular fluid indicated a potential role for this factor in perifollicular angiogenesis and in the regulation of intrafollicular oxygen concentrations. Therefore, VEGF could be a marker for healthy individual follicle but not a clinical prognostic marker for the course of assisted reproduction, which would be consistent with our results. Moreover, the other angiogenesis factors we tested here, sCD31 and sVCAM-1, did not provide any additional information. It should nonetheless be borne in mind that the number of pregnancies in our series was limited and our sample collection design pooled follicular fluid of each woman (as did Friedman et al., 1998) and therefore did not allow identification of processes occurring in single follicles, which is a limitation of our study. However, our data showed that there was no statistically significant difference in the follicular fluid VEGF concentrations in patients conceiving and those failing to conceive. This suggests that VEGF production by granulosa cells is not directly correlated with assisted reproduction outcome or pregnancy potential. VEGF has also been postulated to be a mediator of OHSS (Elchalal and Shenker, 1997; Rizk et al., 1997) but not an important clinical marker for the course of this condition (Ludwig et al., 1998). In this context, a recent study reports that follicular fluid concentrations of VEGF are higher than serum concentrations (Artini et al., 1998). No patient in our study had clinical OHSS, and only four patients had an oestradiol concentration that peaked at >3500 pg/ml on the day of HCG administration. The moderate increase in the follicular fluid concentration of VEGF in some patients, especially those ≥38 years old, might therefore simply reflect the variable ovarian response to gonadotrophin stimulation, rather than serve as a prognostic factor for assisted reproduction outcome. Of the various endothelial markers known, CD31, which corresponds to the intercellular adhesion molecule PECAM-1, has been widely used in immunohistochemical analysis of different tumours (DeYoung et al., 1993). A soluble form of CD31 (sCD31), detected in the serum, has been proposed as a marker of angiogenesis (Goldberger et al., 1994). CD31 is also expressed by the trophoblast (Baldwin et al., 1994) and appears to be involved in the adhesion of trophoblast cells to arterial endothelium during implantation (Blankenship and Enders, 1997). Some authors have also reported that sCD31 might be a predictive marker that could distinguish pre-eclamptic from normotensive pregnant women (Konijnenberg et al., 1997; Krauss et al., 1997). To our knowledge, our study was the first to analyse follicular fluid concentrations of sCD31 in patients treated with assisted reproduction, but we found no correlation between the sCD31 concentration and either the assisted reproduction outcome or patient age. After cell activation, various cytokines induce VCAM-1 expression; it is released in an active soluble form (sVCAM-1) during inflammatory and immune reactions (Gearing et al., 1993; Marik and Lo, 1996). Recent reports indicate that sVCAM-1 concentration in plasma and peritoneal fluid may be a predictive marker of OHSS (Daniel et al., 1999). It is known to be expressed by the oocyte and early embryo (Campbell et al., 1995). Our study confirmed for the first time the existence of sVCAM-1 in the follicular fluid. Like the other angiogenic factors tested in our study, follicular fluid sVCAM-1 does not appear to predict assisted reproduction outcome. Our data did, however, show a highly significant positive relation between follicular fluid sVCAM-1 concentrations and the fertilization rate. This concentration might thus be a marker of fertilization. Besides the gonadotrophin-dependent production of VEGF by granulosa cells, other indications that cytokine interactions may be involved in the local regulation of VEGF production have appeared in recent studies (Cohen et al., 1996; Moncayo et al., 1998). We observed a significant positive correlation between follicular fluid concentrations of sVCAM-1 and of VEGF. Thus, follicular fluid local production of these factors appears to be linked. Finally, our study suggests that both these angiogenic factors (VEGF and VCAM-1) are probably involved in fertilization, but their local regulation is currently unknown. Conclusion In conclusion, we found that VEGF, sCD31 and sVCAM-1 concentrations in follicular fluid were not correlated with assisted reproduction outcome. We were also unable to confirm previous reports that follicular fluid concentrations of VEGF are elevated in older women (≥38 years) undergoing assisted reproduction. Our results also indicated that follicular fluid concentrations of VEGF, sCD31 and sVCAM-1 were similar in women whose infertility stems from different causes (tubal factors, endometriosis, or male factors). Finally, our data suggest that elevated follicular fluid sVCAM-1 concentration may be associated with a high fertilization rate. Elevated follicular fluid concentrations of sVCAM-1 appears therefore to be a fundamental marker of the process of human fertilization. Table I. Characteristics of patients treated with assisted reproduction Characteristics  Groups    Tubal disease  Endometriosis  Male factors  Values are mean ± SD unless otherwise indicated.  The groups did not differ significantly for any parameter, as assessed using the Kruskal-Wallis test.  VEGF = vascular endothelial growth factor; sCD31 = soluble platelet endothelial cell adhesion molecule-1; sVCAM-1 = soluble vascular cell adhesion molecules.  No. of patients  50  12  13  Age (years)  34.7 ± 3.59  32.33 ± 3.42  33 ± 3.34  Oestradiol peak (pg/ml)  2402 ± 843  2334 ± 589  2134 ± 631  No. of ampoules of gonadotrophins  33 ± 16  29 ± 9  35 ± 18  No. of oocytes retrieved  9.32 ± 5.38  8.75 ± 6.2  8.46 ± 3.82  Fertilization rate (%)  56 ± 31.7  46.3 ± 34.4  63.8 ± 22.6  No. of pregnancies  16  1  2  Follicular fluid        VEGF (pg/ml)  2632 ± 1485  3005 ± 2438  3062 ± 1941  sCD31 (ng/ml)  11.2 ± 3.13  11.4 ± 4.28  10.96 ± 4.3  sVCAM-1 (ng/ml)  199.22 ± 93.16  215.53 ± 102.8  186.1 ± 57.9  Characteristics  Groups    Tubal disease  Endometriosis  Male factors  Values are mean ± SD unless otherwise indicated.  The groups did not differ significantly for any parameter, as assessed using the Kruskal-Wallis test.  VEGF = vascular endothelial growth factor; sCD31 = soluble platelet endothelial cell adhesion molecule-1; sVCAM-1 = soluble vascular cell adhesion molecules.  No. of patients  50  12  13  Age (years)  34.7 ± 3.59  32.33 ± 3.42  33 ± 3.34  Oestradiol peak (pg/ml)  2402 ± 843  2334 ± 589  2134 ± 631  No. of ampoules of gonadotrophins  33 ± 16  29 ± 9  35 ± 18  No. of oocytes retrieved  9.32 ± 5.38  8.75 ± 6.2  8.46 ± 3.82  Fertilization rate (%)  56 ± 31.7  46.3 ± 34.4  63.8 ± 22.6  No. of pregnancies  16  1  2  Follicular fluid        VEGF (pg/ml)  2632 ± 1485  3005 ± 2438  3062 ± 1941  sCD31 (ng/ml)  11.2 ± 3.13  11.4 ± 4.28  10.96 ± 4.3  sVCAM-1 (ng/ml)  199.22 ± 93.16  215.53 ± 102.8  186.1 ± 57.9  View Large Table II. Follicular fluid concentrations of VEGF, sCD31 and sVCAM-1 and assisted reproduction outcome Characteristics  Groups  t-Test    1 (not pregnant)  2 (pregnant)  P  Values are mean ± SD unless otherwise indicated.  VEGF = vascular endothelial growth factor; sCD31 = soluble platelet endothelial cell adhesion molecule-1; sVCAM-1 = soluble vascular cell adhesion molecules.  No. of patients  56  19  –  Age (years)  33.7 ± 3.53  34.9 ± 3.8  NS  Oestradiol peak (pg/ml)  2332 ± 720  2384 ± 932  NS  No. of ampoules of gonadotrophins  34 ± 15  31 ± 17  NS  No. of oocytes retrieved  9.04 ± 5.33  9.21 ± 5.07  NS  Fertilization rate (%)  51 ± 31.9  70.1 ± 22.4  0.018  Follicular fluid        VEGF (pg/ml)  2940.7 ± 1847.7  22 53.9 ± 1224.6  NS  Follicular fluid sCD31 (ng/ml)  11.1 ± 3.53  11.3 ± 3.5  NS  Follicular fluid sVCAM-1 (ng/ml)  202.3 ± 94.7  191.6 ± 71.6  NS  Characteristics  Groups  t-Test    1 (not pregnant)  2 (pregnant)  P  Values are mean ± SD unless otherwise indicated.  VEGF = vascular endothelial growth factor; sCD31 = soluble platelet endothelial cell adhesion molecule-1; sVCAM-1 = soluble vascular cell adhesion molecules.  No. of patients  56  19  –  Age (years)  33.7 ± 3.53  34.9 ± 3.8  NS  Oestradiol peak (pg/ml)  2332 ± 720  2384 ± 932  NS  No. of ampoules of gonadotrophins  34 ± 15  31 ± 17  NS  No. of oocytes retrieved  9.04 ± 5.33  9.21 ± 5.07  NS  Fertilization rate (%)  51 ± 31.9  70.1 ± 22.4  0.018  Follicular fluid        VEGF (pg/ml)  2940.7 ± 1847.7  22 53.9 ± 1224.6  NS  Follicular fluid sCD31 (ng/ml)  11.1 ± 3.53  11.3 ± 3.5  NS  Follicular fluid sVCAM-1 (ng/ml)  202.3 ± 94.7  191.6 ± 71.6  NS  View Large Table III. Follicular fluid concentrations of VEGF, sCD31 and sVCAM-1 and pregnancy outcome among women who became pregnant after assisted reproduction Characteristics  Groups  t-Test    Miscarriage  Delivery  P  Values are mean ± SD unless otherwise indicated.  VEGF = vascular endothelial growth factor; sCD31 = soluble platelet endothelial cell adhesion molecule-1; sVCAM-1 = soluble vascular cell adhesion molecules.  No. of patients  5  14  –  Follicular fluid        VEGF (pg/ml)  2740.78 ± 1691.86  2080.09 ± 1035.4  NS  sCD31 (ng/ml)  12.09 ± 2.3  11.08 ± 3.9  NS  sVCAM-1 (ng/ml)  220.73 ± 48.35  181.23 ± 77.01  NS  Characteristics  Groups  t-Test    Miscarriage  Delivery  P  Values are mean ± SD unless otherwise indicated.  VEGF = vascular endothelial growth factor; sCD31 = soluble platelet endothelial cell adhesion molecule-1; sVCAM-1 = soluble vascular cell adhesion molecules.  No. of patients  5  14  –  Follicular fluid        VEGF (pg/ml)  2740.78 ± 1691.86  2080.09 ± 1035.4  NS  sCD31 (ng/ml)  12.09 ± 2.3  11.08 ± 3.9  NS  sVCAM-1 (ng/ml)  220.73 ± 48.35  181.23 ± 77.01  NS  View Large Table IV. Relation between follicular fluid concentrations of VEGF, sCD31 and sVCAM-1 and patient age Characteristics  Groups  t-Test    ≤37 years  ≥38 years  P  Values are mean ± SD unless otherwise indicated.  VEGF = vascular endothelial growth factor; sCD31 = soluble platelet endothelial cell adhesion molecule-1; sVCAM-1 = soluble vascular cell adhesion molecules.  No. of patients  60  15  –  Age (years)  32.8 ± 2.9  38.93 ± 0.8  –  Oestradiol peak (pg/ml)  2439 ± 800  1969 ± 519  0.034  No. of ampoules of gonadotrophins  32 ± 14  36 ± 20  NS  No. of oocytes retrieved  9.47 ± 5.2  7.53 ± 5.5  NS  Fertilization rate (%)  53.6 ± 31  64.5 ± 29.6  NS  Follicular fluid        VEGF (pg/ml)  2741.81 ± 1823.65  2866.31 ± 1337.64  NS  sCD31 (ng/ml)  11.34 ± 3.6  10.47 ± 3.1  NS  sVCAM-1 (ng/ml)  201.45 ± 90.83  192 ± 84.3  NS  Characteristics  Groups  t-Test    ≤37 years  ≥38 years  P  Values are mean ± SD unless otherwise indicated.  VEGF = vascular endothelial growth factor; sCD31 = soluble platelet endothelial cell adhesion molecule-1; sVCAM-1 = soluble vascular cell adhesion molecules.  No. of patients  60  15  –  Age (years)  32.8 ± 2.9  38.93 ± 0.8  –  Oestradiol peak (pg/ml)  2439 ± 800  1969 ± 519  0.034  No. of ampoules of gonadotrophins  32 ± 14  36 ± 20  NS  No. of oocytes retrieved  9.47 ± 5.2  7.53 ± 5.5  NS  Fertilization rate (%)  53.6 ± 31  64.5 ± 29.6  NS  Follicular fluid        VEGF (pg/ml)  2741.81 ± 1823.65  2866.31 ± 1337.64  NS  sCD31 (ng/ml)  11.34 ± 3.6  10.47 ± 3.1  NS  sVCAM-1 (ng/ml)  201.45 ± 90.83  192 ± 84.3  NS  View Large Figure 1. View largeDownload slide Relationship between follicular fluid concentrations of vascular endothelial growth factor (VEGF) and number of gonadotrophin ampoules administered (A), follicular fluid concentrations of soluble vascular cell adhesion molecules (sVCAM) and fertilization rate (B), follicular fluid concentrations of VEGF and of sVCAM (C) individually for all patients. Spearman's rank correlation (ρ) was determined. Figure 1. View largeDownload slide Relationship between follicular fluid concentrations of vascular endothelial growth factor (VEGF) and number of gonadotrophin ampoules administered (A), follicular fluid concentrations of soluble vascular cell adhesion molecules (sVCAM) and fertilization rate (B), follicular fluid concentrations of VEGF and of sVCAM (C) individually for all patients. Spearman's rank correlation (ρ) was determined. 4 To whom correspondence should be addressed at: Hopital Rothschild, 33 Bd de Picpus, 75012 Paris, France.E-mail: jl.benifla@rth.ap-hop-paris.fr The authors wish to thank A.Neuraz, M.Naouri and A.Devaux for their help in data collection, Jo Ann Cahn and Janet Jacobson for the translation of this manuscript. References Abramov, Y., Barak, V., Nisman, B. and Schenker, J.G. ( 1997) Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil. Steril. , 67, 261–265. Google Scholar Adashi, E.Y. ( 1992) Intraovarian peptides. Endocrinol. Metab. Clin. North Am. , 21, 1–17. Google Scholar Almendro, N., Bellon, T., Rius, C. et al. ( 1996) Cloning of the human platelet endothelial cell adhesion molecule-1 promoter and its tissue-specific expression. Structural and functional characterization. J. Immunol. , 12, 5411–5421. Google Scholar Anasti, J.N., Kalantaridou, S.N., Kimzey, L.M. et al. ( 1998) Human follicle fluid vascular endothelial growth factor concentrations are correlated with luteinization in spontaneously developing follicles. Hum. Reprod. , 13, 1144–1147. Google Scholar Artini, P.G., Fasciani, A., Monti, M. et al. ( 1998) Changes in vascular endothelial growth factor levels and the risk of ovarian hyperstimulation syndrome in women enrolled in an in vitro fertilization program. Fertil. Steril. , 70, 560–564. Google Scholar Baldwin, H.S., Shen, H.M., Yan, H.C. et al. ( 1994) Platelet endothelial cell adhesion molecule (PECAM-1/CD31): alternatively spliced functionally distinct isoforms expressed during mammalian cardiovascular development. Development , 120, 2539–2553. Google Scholar Banks, R.E., Gearing, A.J.H., Hemingway, I.K. et al. ( 1993) Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br. J. Cancer , 68, 122–124. Google Scholar Blankenship, T.N. and Enders, A.C. ( 1997) Expression of platelet-endothelial cell adhesion molecule-1 (PECAM) by macaque trophoblast cells during invasion of the spiral arteries. Anat. Rec. , 247, 413–419. Google Scholar Campbell, S., Swann, H.R., Seif, M.W. et al. ( 1995) Cell adhesion molecules on the oocyte and preimplantation human embryo. Hum. Reprod. , 10, 1571–1578. Google Scholar Christenson, L.K. and Stouffer, R.L. ( 1997) Follicle-stimulating hormone and luteinizing hormone/chorionic gonadotropin stimulation of vascular endothelial growth factor production by macaque granulosa cells from pre- and periovulatory follicles. J. Clin. Endocrinol. Metab. , 82, 2135–2142. Google Scholar Cohen, T., Nahari, D., Cerem, L.W. et al. ( 1996) Interleukin 6 induces the expression of vascular endothelial growth factor. J. Biol. Chem. , 271, 736–741. Google Scholar Cotran, R.S. and Mayadas-Norton, T. ( 1998) Endothelial adhesion molecules in health and disease. Pathol. Biol. , 46, 164–170. Google Scholar Daniel, Y., Geva, E., Amit, A. et al. ( 1999) Levels of soluble vascular cell adhesion molecule-1 and soluble intercellular adhesion molecule-1 are increased in women with ovarian hyperstimulation syndrome. Fertil. Steril. , 71, 896–901. Google Scholar DeYoung, B.R., Wick, M.R., Fitzgibbon, J.F. et al. ( 1993) CD31: an immunospecific marker for endothelial differentiation in human neoplasms. Appl. Immunohistochem. , 1, 97–100. Google Scholar Elchalal, U. and Schenker, J.G. ( 1997) The pathophysiology of ovarian hyperstimulation syndrome | view and ideas. Hum. Reprod. , 12, 1129–1137. Google Scholar Ferrara, N., Houck, K., Jakeman, L. and Leung, D.W. ( 1991) The vascular endothelial growth factor family of polypeptides. J. Cell. Biol. , 47, 211–218. Google Scholar Ferrara, N., Houck, K., Jakeman, L. and Leung, D.W. ( 1992) Molecular and biological properties of the VEGF family of proteins. Endocr. Rev. , 1, 18–32. Google Scholar Friedman, C.I., Arbogast, L., Danforth, D.R. et al. ( 1997) Follicular fluid vascular endothelial growth factor concentrations are elevated in women of advanced reproductive age undergoing ovulation induction. Fertil. Steril. , 68, 607–612. Google Scholar Friedman, C.I., Seifer, D.B., Kennard, E.A. et al. ( 1998) Elevated level of follicular fluid vascular endothelial growth factor is a marker of diminished pregnancy potential. Fertil. Steril. , 70, 836–839. Google Scholar Gearing, J.H., Hemingway, I., Pigott, R. et al. ( 1993) Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1 and VCAM-1: pathologic significance. Ann. NY Acad. Sci. , 40, 324–331. Google Scholar Goldberger, A., Middleton, K.A., Oliver, J.A. et al. ( 1994) Biosynthesis and processing of the cell adhesion molecule PECAM-1 includes production of a soluble form. J. Biol. Chem. , 269, 17183–17191. Google Scholar Kamat, B.R., Brown, L.F., Manseau, E.J. et al. ( 1995) Expression of VPF/VEGF by human granulosa and theca lutean cells: role in corpus luteum development. Am. J. Pathol. , 146, 157–165. Google Scholar Konijnenberg, A., Stokkers, A.W., Van Der Post, J.A.M. et al. ( 1997) Extensive platelet activation in preeclampsia compared with normal pregnancy: enhanced expression of cell adhesion molecules. Am. J. Obstet. Gynecol. , 176, 461–469. Google Scholar Krauss, T., Kuhn, W., Lakoma, C. and Augustin, H.G. ( 1997) Circulating endothelial cell adhesion molecules as diagnostic markers for the early identification of pregnant women at risk for development of preeclampsia. Am. J. Obstet. Gynecol. , 177, 443–449. Google Scholar Lee, A., Christenson, L.K., Stouffer, R.L. et al. ( 1997) Vascular endothelial growth factor levels in serum and follicular fluid of patients undergoing in vitro fertilization. Fertil. Steril. , 68, 305–311. Google Scholar Ludwig, M., Bauer, O., Jelkmann, W. and Dietrich, K. ( 1998) Serum concentration of vascular endothelial growth factor cannot predict the course of severe ovarian hyperstimulation syndrome. Hum. Reprod. , 13, 30–32. Google Scholar Manau, D., Balasch, J., Jimenez, W. et al. ( 2000) Follicular fluid concentrations of adrenomedullin, vascular endothelial growth factor and nitric oxide in IVF cycles: relationship to ovarian response. Hum. Reprod. , 15, 1295–1299. Google Scholar Marik, A.B. and Lo, A.S. ( 1996) Vascular endothelial molecules and tissue inflammation. Pharmacol. Rev. , 48, 213–229. Google Scholar Moncayo, H.E. and Moncayo, R. ( 1995) Perspectives on ovarian dysfunction and autoimmunity. Horm. Metab. Res. , 12, 544–546. Google Scholar Moncayo, H.E., Penz-Koza, A., Marth, C. et al. ( 1998) Vascular endothelial growth factor in serum and in the follicular fluid of patients undergoing hormonal stimulation for in-vitro fertilization. Hum. Reprod. , 13, 3310–3314. Google Scholar Neulen, J., Zhaoping, Y., Raczek, S. et al. ( 1995) Human chorionic gonadotropin dependent expression of vascular endothelial growth factor in human granulosa cells and importance in ovarian hyperstimulation syndrome. J. Clin. Endocrinol. Metab. , 80, 1967–1971. Google Scholar Ravindranath, L., Little-Ihring, L.L., Phillips, H.S. et al. ( 1992) Vascular endothelial growth factor messenger ribonucleic acid expression in primate ovary. Endocrinology , 131, 254–260. Google Scholar Rizk, B., Aboulghar, M., Smitz, J. et al. ( 1997) The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation. Hum. Reprod. Update , 3, 255–266. Google Scholar Van Blerkom, J., Antczak, M., Schrader, R. ( 1997) The developmental potential of the human oocyte is related to the dissolved oxygen content of follicular fluid: association with vascular endothelial growth factor levels and perifollicular blood flow characteristics. Hum. Reprod. , 12, 1047–1055. Google Scholar Yan, Z., Weich, H.A., Bernart, W. et al. ( 1993) Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cell in vitro. J. Clin. Endocrinol. Metab. , 77, 1723–1725. Google Scholar © European Society of Human Reproduction and Embryology
TI - Vascular endothelial growth factor, platelet endothelial cell adhesion molecule-1 and vascular cell adhesion molecule-1 in the follicular fluid of patients undergoing IVF
JO - Human Reproduction
DO - 10.1093/humrep/16.7.1376
DA - 2001-07-01
UR - https://www.deepdyve.com/lp/oxford-university-press/vascular-endothelial-growth-factor-platelet-endothelial-cell-adhesion-0PsFk0yov1
SP - 1376
EP - 1381
VL - 16
IS - 7
DP - DeepDyve
ER -